医学
中性粒细胞减少症
胸腺瘤
环磷酰胺
胸腺癌
内科学
化疗
顺铂
氮芥
外科
进行性疾病
放射治疗
胃肠病学
肿瘤科
作者
Patrick J. Loehrer,KyungMann Kim,Seena C. Aisner,Robert B. Livingston,Lawrence Einhorn,Clifton D. Fuller,Rob Blum
标识
DOI:10.1200/jco.1994.12.6.1164
摘要
The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival.Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy.Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR+PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+).This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI